Medical Disorders
Basic InformationLookupsLatest News
AHA News: Lung Injuries Should Be a Warning About Vaping's RisksDangerous Ink: Tattoos Might Lead to Body's OverheatingMental Health Issues Double the Odds of Dying With COVID-19, Study FindsStudy Sheds Light on Why COVID-19 Hits Elderly HardestDuring Stress of Pandemic, Know Suicide's Warning SignsEarly Results Show Moderna's COVID Vaccine Safe, Effective in Older PeoplePandemic Has More Americans Turning to BoozeStudy Confirms Minorities Face Higher Odds of COVID-19: StudyLockdown Could Worsen Hearing Woes for U.S. SeniorsGlobal Death Toll From COVID-19 Passes One MillionWarming World Could Alter West Nile Transmission in U.S.Most Newborns of COVID-19-Infected Moms Fare WellCOVID Antibodies Found in Less Than 10% of AmericansCOVID-19 Patients Rarely Survive Cardiac Arrest: StudyLow Vitamin D Levels Tied to Higher Odds for Severe COVIDKids Much Less Prone to Coronavirus Infection Than Adults: StudyImmune System Clues to Why COVID Is Easier on KidsU.S. Coronavirus Cases Top 7 MillionAccuracy of COVID-19 Antibody Tests Varies Widely, Study FindsAmerica's COVID Pandemic Is Now Skewing YoungerEven If Hips, Legs Slim Down, Belly Fat Remains a Health DangerAfter COVID-19 Exposure, When Can Young Athletes Resume Play?Kids Who Need Steroids Face Risk of Diabetes, Other Ills9 in 10 Americans Not Yet Immune to COVID, CDC Director SaysBlood Test Could Spot Those at Highest Risk for Severe COVID-19Singing Without a Face Mask Can Spread COVID-19U.S. COVID Death Toll Hits 200,000 as Cases Climb in 22 States4 Out of 5 People With COVID-19 Will Develop Symptoms: StudyMany Health Care Workers Who Have Coronavirus Don't Have Symptoms: StudyAHA News: Cluster of Risky Conditions That Can Lead To Heart Disease Is Rising in Hispanic AdultsMinorities Hit Hardest When COVID Strikes Nursing HomesAvoid the 'Twindemic:' Get Your Flu Shot NowCertain Cancer Treatments May Heighten Danger From COVID-19Homemade Masks Do a Great Job Blocking COVID-19Having Flu and COVID Doubles Death Risk in Hospitalized PatientsGuard Yourself Against the Health Dangers of Wildfire SmokeLife Expectancy Could Decline Worldwide Due to COVID-19Potential COVID-19 Drug Could Increase Heart Risk: StudyU.S. COVID Death Toll Nears 200,000, While Cases Start to Climb AgainCDC Reverses COVID Test Guideline After ControversyAs Schools Reopen, Many Students, Staff Live With High-Risk Family MemberCOVID-19 Poses Added Risk for People With Addiction Disorders: StudyGetting a Hip Replacement? Choice of Hospital Can Be CrucialAlmost 90,000 Young American Adults Will Get Cancer This Year: ReportAnother Rapid COVID-19 Test Shows PromiseDetails Emerge on Unexplained Illness in AstraZeneca COVID Vaccine TrialRising Obesity Levels Put Americans at Risk During Pandemic: CDCMore Pets May Be Getting COVID-19 Than RealizedWildfire Smoke Poses Special Threat to People With AsthmaCOVID-19 Prevention Might Translate Into Record Low Flu Rates: CDC
Questions and AnswersVideosLinksBook Reviews
Related Topics

Men's Health
Women's Health

Parkinson's Drug Eyed as Treatment for Severe Macular Degeneration

HealthDay News
by By Serena McNiff
HealthDay Reporter
Updated: Sep 16th 2020

new article illustration

WEDNESDAY, Sept. 16, 2020 (HealthDay News) -- A drug long used to treat Parkinson's disease may benefit patients with a severe form of age-related macular degeneration (AMD), a small clinical trial suggests.

One of the leading causes of vision loss in older people is a condition called dry macular degeneration. More than 15% of Americans over age 70 have AMD, and 10% to 15% of those cases go on to develop the more severe wet macular degeneration, which can cause swift and complete vision loss.

Typically, wet AMD is treated with injections of medication into the eye. Most people need several per year to keep the disease from progressing.

But this small, early-stage clinical trial suggests an alternative may be on the horizon: the leading drug used to treat Parkinson's disease, called levodopa.

The trial was an outgrowth of a 2016 study that found Parkinson's patients who took levodopa were less likely to develop macular degeneration.

"The study found a relationship between taking levodopa and macular regeneration," said Dr. Robert Snyder, a professor of ophthalmology at the University of Arizona, in Tucson. "It delayed the onset of both dry and wet macular degeneration, and reduced the odds of getting wet macular degeneration."

Macular degeneration affects the macula, part of the eye that allows you to see fine detail. Wet AMD happens when abnormal blood vessels grow under the macula; often, these blood vessels leak blood and fluid, causing rapid damage.

Snyder and two colleagues began a clinical trial in 2017 to learn whether levodopa might help prevent both forms of AMD.

Twenty patients newly diagnosed with AMD took part in the first trial. Each was given a small daily dose of levodopa for one month.

An eye doctor evaluated them weekly to determine whether they also needed an eye injection. Since the trial was based on preliminary research, the authors wanted patients to receive injections if necessary, to ensure that their condition wouldn't worsen if the levodopa was ineffective.

"Instead of injecting them, which would have been the standard of care, we treated them with levodopa and followed them weekly to make sure they didn't get worse," Snyder said. "And if they did get worse, we sent them back for an injection."

After one month, all participants joined 11 new enrollees in a second trial to evaluate levodopa's safety and effectiveness at different doses.

While many participants needed an injection during the trial, they required fewer shots than would normally be given during a one-month period. Taking levodopa also seemed to delay the need for an injection, the study found.

The authors reported that taking levodopa improved participants' vision overall. It also significantly decreased the buildup of fluid in the eye.

The drug was shown to be safe and well-tolerated, the researchers said. Patients who experienced side effects associated with the medication, such as nausea and blurred vision, were placed on a lower dose.

But this sort of "open-label trial" has some limitations. There was no point of comparison, such as a placebo; all participants received levodopa. And researchers and participants all knew what treatment was administered, potentially introducing bias to the results.

Dr. Raj Maturi, clinical spokesman for the American Academy of Ophthalmology, said confirming the drug's safety and effectiveness will require a larger, more robust clinical trial.

Maturi also expressed concern about potential side effects of levodopa, especially given the age of the population that is affected by macular degeneration.

"You're talking about a population of their 70s and 80s -- they already have other things going on," Maturi said. "An additional oral systemic drug that they will take for the rest of their life can significantly affect their quality of life. I'm always concerned about the side effect profiles of oral drugs that have to be taken for a long period of time."

While the second part of the trial is ongoing, early results were published online recently in The American Journal of Medicine. Snyder said a larger study is forthcoming.

"We felt pretty strongly that we had a positive effect and had a proof of concept to go forward with a larger, placebo-controlled clinical trial," he said. "That's going to be our next step."

More information

There's more about wet macular degeneration at the U.S. National Eye Institute.


Amazon Smile


Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.


powered by centersite dot net